|
|
|
| Prognostic Prediction Value of Serum Procalcitonin Combined with Lactate Dehydrogenase in Children with Severe Pneumonia |
| TIAN Minrong, CHEN Qiufang |
| Department of Pediatrics, Taiqian New District Hospital, Puyang Henan 457600 |
|
|
|
|
Abstract 【Objective】To explore the predictive value of procalcitonin (PCT) combined with lactate dehydrogenase for the prognosis of children with severe pneumonia. 【Methods】A retrospective analysis was conducted on the clinical data of 70 children with severe pneumonia treated in Taiqian New District Hospital from January 2019 to January 2022. The patients were divided into a poor prognosis group and a good prognosis group based on whether they had a recurrence of pulmonary infection after treatment. The clinical data of the two groups were compared. Logistic multivariate regression analysis was used to identify the influencing factors of poor prognosis in children with severe pneumonia. The area under the receiver operating characteristic (ROC) curve (AUC) was used to evaluate the predictive value of PCT, lactate dehydrogenase levels, and their combination for poor prognosis in children with severe pneumonia. 【Results】The incidence of poor prognosis in 70 children with severe pneumonia after treatment was 14.29% (10/70). The levels of PCT and lactate dehydrogenase in the poor prognosis group were higher than those in the good prognosis group (P<0.05), and the proportion of agranulocytosis was higher than that in the good prognosis group (P<0.05). Logistic multivariate regression analysis showed that agranulocytosis and high levels of lactate dehydrogenase and PCT were risk factors for poor prognosis in children with severe pneumonia (P<0.05). ROC curve analysis showed that the AUC values of PCT, lactate dehydrogenase, and their combination for predicting poor prognosis in children with severe pneumonia were 0.870, 0.859, and 0.936, respectively. 【Conclusion】The proportion of poor prognosis in children with severe pneumonia is relatively high. PCT and lactate dehydrogenase have certain predictive value for poor prognosis in children with severe pneumonia, and their combination has a higher predictive value.
|
|
Received: 24 August 2024
|
|
|
|
|
|
[1] COWAN A J, GREEN D J, KWOK M, et al. Diagnosis and management of multiple myeloma: a review[J].JAMA,2022,327(5):464-477.
[2] PAWLYN C, DAVIES F E. Toward personalized treatment in multiple myeloma based on molecular characteristics[J].Blood,2019,133(7):660-675.
[3] 刘晓曼,陈旭,张新征. 重症肺炎患者C-反应蛋白、磷酸肌酸激酶同工酶及乳酸脱氢酶水平变化及临床意义[J].实用医院临床杂志,2022,19(3):174-177.
[4] 苏华,李键,侯有华,等. 血清乳酸脱氢酶评估颅脑手术患者重症肺炎的临床价值[J].现代生物医学进展,2023,23(12):2377-2381.
[5] GASPARETTO C, SCHILLER G J, TUCHMAN S A, et al.Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients[J].Br J Cancer,2022,126(5):718-725.
[6] 中国医师协会急诊医师分会. 中国急诊重症肺炎临床实践专家共识[J].中国急救医学, 2016, 36(2):97-107.
[7] DESHMUKH T, VARMA A, DAMKE S, et al. Predictive efficacy of pediatric logistic organ dysfunction-2 score in pediatric intensive care unit of rural hospital[J].Indian J Crit Care Med,2020, 24(8):701-704.
[8] 黄赛虎, 孟祥营, 张建平, 等. 重症肺炎患儿肺泡灌洗液病原学分析及临床特点[J].中华实用儿科临床杂志, 2021, 36(4):262-266.
[9] 赵明丽,廖敏,王玉忠. 重症肺炎患者乳酸脱氢酶、载脂蛋白A1、铁蛋白水平与病情的关系及预后意义[J].中华肺部疾病杂志(电子版),2023,16(2):233-235.
[10] 彭美玲,张雪梅. 使用蒽环类药物化疗的恶性肿瘤患者发生慢性心脏毒性的影响因素分析[J].医学临床研究,2024,41(4):551-554.
[11] 刘晓晖,高洪亮,白雪. 肺部超声检查联合PCT、CRP检测在重症肺炎并发ARDS患者中的应用价值[J].医学临床研究,2022,39(5):701-704.
[12] 杨智娟,占玮,李耀才. PCT、CD4+/CD8+水平变化与重症肺炎预后的关系研究[J].中国医学创新,2021,18(11):41-45.
[13] 张健,李兰,范世明. CD64指数、sTREM-1、CRP/Alb比值对重症肺炎患者的诊断和预后价值分析[J].热带医学杂志,2019,19(7):890-893. |
|
|
|
2025, Vol. 42 
